Multiple Antigen Presenting System News Today

Researchers are testing new ways to protect against infectious disease – and pursuing effective vaccines that have eluded them for decades.

GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.

LONDON (dpa-AFX) - GSK plc (GSK.L) on Tuesday said it has completed the acquisition of clinical-stage biopharmaceutical company Affinivax, Inc. The definitive deal was announced by GSK in May this

GSK completes acquisition of Affinivax

GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation ...

GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones ...

GSK will pay up to $3.3bn to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and vaccine candidates.

GSK to acquire clinical-stage biopharmaceutical company Affinivax

While the last two years have seen the successful development of COVID-19 vaccines, the emergence of variants highlights the speed at which the pandemic - or indeed any other virus threat - can evolve. As a result, development of novel vaccine candidates that could offer broad protection is being stepped up.

Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Affinivax, Inc. ("Affinivax") an...